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Background:
Disease stratification practices have long been used as a means to produce
and make sense of  cancer, distinguishing ‘types’, tumour development stages,
and even patients’ sociodemographic profiles. However, interest in
stratification; that is, the process of dividing oncology populations into
clinically meaningful subtypes, has been re-invigorated by two recent
developments in medicine and healthcare. First, an increased awareness of
the multiplicity of bodies, subjectivities and lived situations that must be
coordinated in order to achieve “good care” (Mol 2008, Puig de la Bellacasa
2011). Second, a growing understanding of the potentiality and challenges of
genomic medicine, and the profound ways in which it is informing not only
categories of cancer risk and prognosis, but also wider practices of cancer
prevention, cancer surveillance, and pharmacological development (Kerr et
al. 2019, Cambrosio et al. 2018). Current approaches in cancer care might
therefore be reconfiguring longstanding forms of biological and social
stratification, with important implications for patient experience. Only by
unpacking the practices, hopes and dilemmas of multiple stakeholders can we
begin to grasp what is at stake for cancer patients in the production of new
disease categories and treatment options.
The workshop:
On Friday 12th June, the Department of Social Anthropology at the
University of Cambridge hosted the symposium ‘Ethnographies of disease
stratification: Understanding novel clinical practices and their social
consequences in contemporary cancer care’
(https://www.socanth.cam.ac.uk/events/symposium-ethnographies-of-
disease-stratification-understanding-novel-clinical-practices-and-their-social-
consequences-in-contemporary-cancer-care). With the generous support of
the Foundation for the Sociology of Health and Illness, seven papers
interrogated current practices and consequences of stratification emerging in
Brazil, Greece, Canada, France and the UK. Ethnographic work in these
various sites was discussed by an audience of students and researchers in




/The workshop sought to provide a multidisciplinary platform to critically
examine the practices of stratification themselves and the social effects they
generate for the communities with which we work. We asked how
stratification practices emerge in our fields and how research participants —
researchers, health professionals, patients and caregivers — negotiate their
effects in everyday life. Drawing on ethnographic insights from several sites
around the world, we looked at the scope, limits and consequences of disease
stratification practices, and how they re-articulate older forms of social and
biological stratification. Connecting longstanding and novel practices of
stratification, we argued, may offer the possibility to understand wider
processes of biomedical innovation and the stakes of these processes for the
people who engage with cancer biomedicine today.
Overall, the conversations held during the day prompted us to question
whether and how the vocabulary of stratification contributes to an improved
understanding of the practices and experiences around cancer today. In this
post, we present two interrelated themes within this realm: classificatory
practices in research and care, and the (dis)continuities of treatment
“personalisation” via targeted therapies.
Situating stratification practices within the realm of cancer research and
care:
Through presentations detailing the ethnographic situations in which
practices of social stratification emerge and become observable, we learned
how age, “red flags” as diagnostic tools, and indigenous belonging are utilised
as criteria for the coordination of health interventions in cancer. Practices of
classification and prioritization structure the research and clinical work in
cancer biomedicine. Classificatory practices are often required to make
research outputs valid for a specific study population, to prioritise access to
healthcare services, and to decide between treatment approaches. However,
the criteria that is used (or not used) to sort through clinical cases might also
limit the quality and equality of clinical care; engaging with some people and
silencing others (see Bowker and Star, 1999).
Benjamin Derbez (with co-author Meoïn Hagège, both from University of
Western Brittany)  described the bias posed by studies that seek to determine
the effectiveness of therapeutic treatments, when protocols to recruit
research participants do not include the elderly population in randomised
cancer control clinical trials in France. The exclusion of the elderly defies the
idea of “universal biology” that underpins the practice of clinical trials
through the definition of inclusion and exclusion criteria (see Lock and
Nguyen 2010). In this context, Derbez asked: “Under equivalent living
conditions, is it possible to identify biological age limits causing a man or a
woman of similar ethnic origin to be considered as within the ‘adult’ or the
‘elderly’ categories?” From this talk, we learned how for professionals in
Oncogeriatry, age is translated into biological frailty (see Akrich, Callon and
Latour, 2006), realigning the work of geriatricians and oncologists in Geriatric
Oncology Coordination Units in the French metropolitan area. This
realignment work, Derbez argued, in turn enables the construction of clinical
evidence in pharmacological development that is made meaningful for the
elderly population.
Moving from research to treatment practices, referral and triage, Steph
Meysner (University of Liverpool) described one of the consequences of
prioritising red flag symptoms in the diagnosis of head and neck cancer in
Northern England. Through the analysis of two patient itineraries, we learned
that “warning” or “dangerous” symptoms are not conceived as independent
outcomes from patients’ sociodemographic characteristics, their assumed
behaviours, and the health professionals who use them to describe clinical
cases. Looking at the use of red flag symptoms to understand the problem of
“late presentation” of patients affected by head and neck cancers, Meysner
described the dire consequences of a long-standing form of social
stratification based on professionals’ assumptions. Even though red flag
symptoms are useful to identify some patients and speed up diagnosis,
/confounding red flag symptoms with stereotypes held by some health
professionals in primary and secondary care poses the risk of delaying the
diagnosis and treatment of some people who seek healthcare advice early on.
Another source of internal differentiation within treatment approaches
concerns the current revitalization of indigenous forms of healing within
national health services. Cathy Fournier (with co-author Robin Oakley, both
from Dalhousie University in Halifax) invited us to reflect on the overall
incongruence of treatment experiences that people affected by different types
of cancer report when one’s own vision of the world and belonging is not
acknowledged in the therapeutic relationship in a Canadian cancer clinic.
Fournier explained that: “Not only is our body, mind and spirit separated
during the clinical encounter, but we tend to be stripped away from our
physical and social environment as well.” Thinking about her own cancer
experience and deploying an indigenous analytical framework of multiplicity,
she elaborated on how indigenous forms of healing could indeed complement
other forms of therapy, rather than being assimilated into mainstream forms
of care.
The molecularisation of cancer care:
The biomedical ability to target specific molecular features of tumours is
driving clinical innovation towards more precise diagnoses and more effective
treatments by way of “stratification”—that is, the process of dividing oncology
populations into clinically meaningful subtypes based on molecular
biomarkers. While these innovations raise hopes for more effective
treatments with fewer side effects, they provoke major dilemmas around
individual and population-wide treatment decisions, equity of treatment
access, and the social configurations of care. 
a. The problem of access
Drawing on sociological and anthropological approaches to medicine, several
presentations demonstrated some of the ways in which current practices of
stratification in cancer research and care may reproduce longstanding
inequalities, raising questions of access to treatment and social justice. Falia
Varelaki and Jorge Alberto Bernstein Iriart discussed the difficulties of
navigating access to new cancer targeted medicines and diagnostic tests in
Greek and Brazilian oncology, respectively. Combining perspectives from
patients and clinicians, both demonstrated that as public healthcare
institutions become unable to afford some of the biomedical innovations for
all their eligible users, the economic cost of receiving new treatments is
transferred to patients and their families, while a moral cost is also shared by
clinical staff members.
Falia Varelaki (University of the Aegean) explained how the use of an
Oncotype diagnostic test in Greece transforms the citizen into a medical
consumer. This molecular test is used by clinicians to assess the risk of distant
recurrence from breast cancer among patients who have had tumours
resected. The higher the risk score, the higher the possibility that
chemotherapy after surgery will be beneficial. However, it is a test that costs
five times the minimum wage in Greece and may only be reimbursed by the
public health service after it has been purchased by patients. The demand for
cash in order to access the test, Veralaki argues, puts the responsibility for
health on the shoulders of patients, creating frustration for those who, even
when eligible, cannot afford it. In the stark words of one of her female
research participants: “Either you have money and you plan your treatment,
or you don’t have money and you plan your death.”
Frustration at seemingly impossible access to health interventions also
appears ethnographically when looking at experiences of oncologists
providing cancer care in Brazil. Jorge Bernstein (from University of Bahia
with co-author Sahra Gibbon from University College London) explained in
his presentation that treatment protocols were different depending on both
patients’ health plans and the cancer centre that they would access in
/Salvador city. Thus, variations in care and treatment depended on the
economic status of the patient, but also on the specific agreements that
centres have secured with the pharmaceutical industry or other research
studies that provided health interventions on trial. Some pharmaceutical
companies offered diagnostic tests for free, with the hope that patients could
request the associated high cost drugs in court – a procedure, called
judicialization, now officially disincentivized in the city of Salvador, and
which takes time and requires resources that are limited for many patients.
These differences, in turn, created an ethical conundrum for clinicians, who
sometimes reflected on whether they should prescribe only what families
could afford without recurring to courts. As Jorge explained: “The doctor is,
as a result, at the centre of an ethical conflict between the imperative to do
the best for his patient and the institutional and governmental pressures to
reduce costs of high-cost drugs through the courts.”
Together, these presentations illuminate how the incorporation of new tests
and treatments widens existing health inequalities, significantly affecting the
already unequal distribution of health outcomes in the population.
b. Molecular stratification and the (im)possibilities therein
Biomarkers signal biological mechanisms amenable to observation by
researchers in wet labs. Pharmacogenomics promises the ability to
manipulate some of these mechanisms, and therefore turn on or off the
expression of certain proteins during oncogenesis. Targeted treatment
approaches such as immunotherapy have made significant gains with the
discovery of these markers, reconfiguring local understandings and capacities
for treatment, and therefore the “local biologies” of cancer (Lock et al, 2001).
Examining the potential of targeted medicines for the treatment of breast and
bowel cancer, Ignacia Arteaga (University of Cambridge) and Cinzia Greco
(University of Manchester) discussed the multiple ways in which the
development of targeted medicines to treat specific subtypes of cancer are
relationally situated within the landscape of personalised medicine in the UK.
Arteaga and Greco looked at the promissory potential of novel approaches to
treatment for metastatic cancer and the practices required from patients to
take part in this endeavour (see Prainsack, 2017). They analysed the complex
processes patients go through in order to obtain this type of treatment,
including fundraising in the community, mortgaging a house, or publicizing
personal stories via the internet to crowdsource the cost of the drug. More
specifically, from Arteaga’s work, we heard about a pharmacogenetic
approach to metastatic colorectal cancer that targets one aspect of a tumour’s
genetic makeup: microsatellite instability. The ability to distinguish high
versus low instability in tumour tissues enables clinicians to understand why
some patients’ cancer are resistant to widely used chemotherapeutic agents
(such as 5Fu), which allows clinicians to choose different treatment
approaches. One such treatment approach is immunotherapy, which seems to
offer the possibility of prolonging the survival of some patients who would
otherwise be facing a lack of therapeutic options. However, it also adds new
health challenges, as patients’ bodies deteriorate and tumours evolve. The
benefits are promissory, but only partial, as a wide segment of the population
does not carry the molecular mutation or cannot pay for the treatment. As
Greco’s work showed, there are many situations in which the promise of
targeted therapies cannot materialise, and the real potential of personalised
medicines diminishes. Some of these include the existence of molecular
receptors not yet amenable for intervention (such as Triple Negative Breast
Cancer); unanticipated ways in which tumours’ biologies evolve; strong and
debilitating side effects; high costs of therapy that are not affordable and the
inability to carry out successful biopsies because of the position of the tumour
in patients’ bodies. Looking at the treatment experiences of women with
metastatic breast cancer, Greco argued that this kind of failure makes
clinicians resort to older and less fashionable treatment approaches that
nevertheless still work as the main staple for several subtypes of cancer.
Importantly, these do not pose the same financial challenge for services and
patients than new targeted medicines do.
/Conclusion: “The elephants in the room”
A lively discussion took place with discussants Professor Sophie Day, Dr
Maryon McDonald and Dr Carsten Timmermann. They reflected on the
theoretical utility of the concept of stratification for the analysis of cancer
experiences and treatments, where distinctions never seem to be clear-cut
and mechanistic understandings of the body gloss over the complexities and
unknowns of tumour development for many types of cancer. Moreover, they
discussed the relevance of ethnographic approaches to critically unpack the
promises and limitations of personalisation practices in medicine, allowing
for greater attention to the practices and experiences that make up hyped
treatment approaches. The discussion included encouraging awareness of the
ways in which scientific evidence is constructed and communicated; and the
ways in which research participants navigate the ethical issues that arise from
these practices in the communities where ethnographies take place.
The discussion which followed with the audience, including a mix of students
and professionals involved in health research, from genetics, to business,
philosophy and the social sciences, converged towards an identification of the
“elephants in the room” that were present throughout the day. Themes
included, first, the potential financial unsustainability of ever more expensive
drugs to treat ever smaller disease populations based on (often provisional)
genomic knowledge. A second aspect concerned the uncertainty that affects
the work done by researchers, patients, clinicians and even policy-makers.
‘Not-knowing’ structures practices and experiences of biomedical innovation
as much as what we know about cancer (see Kerr et al, 2019). A final point
concerned the need for a long-term view of the effects of integrating new
clinical practices in order to assess their transformative potential; and the
ethical stakes we find in situations in which biomedical innovation practices
and claims for social justice meet.
Note: This event has been jointly organised by a group of postdoctoral
researchers: Ignacia Arteaga, Cinzia Greco, Henry Llewellyn, Emily Ross and
Julia Swallow
Statement of authors’ contribution: The first draft of this post was written
by Ignacia Arteaga. Cinzia Greco, Henry Llewellyn, Julia Swallow and Emily
Ross critically revised the draft, offering essential improvements.
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